医疗器械企业计划进入IPO，这个阶段非常重要，但企业往往 比任何时候都"不敢说话" 。 招股书写了什么？ 因此联盟组织此次小范围交流，活动信息如下： 时间： 2026 年 1 月 15 日（星期四）14:30–16:30 地点： 上海徐汇区（报名后可查看详细地址） 哪些信息可以被解读、被使用？ 上市前后，企业还能不能对外发声？ 市场部、品牌部在这一阶段，到底该做什么，又不该做什么？ 这些问题，很少被系统讲清楚，更多依靠券商等上市团队，不同部门的人接触程度不同，可能也需要拼凑经 验。 （二）IPO 前后企业传播的合规边界 主办方： 思宇MedTech、中国眼界、 中关村联新生物医药产业联盟 活动形式： 适合人群： 活动免费，但报名有审核，报名方式附文末。 主要议程： 小范围现场闭门交流（10–15 人） 以讲解 + 讨论为主，欢迎有相关经验的资深人士参与 正在或计划 IPO 的医疗器械企业市场 / 品牌负责人 企业管理层、战略负责人 其他对医疗器械 IPO 传播与合规有实际需求的从业者 1.与会者自我介绍 2.主分享嘉宾讲PPT 分享嘉宾： 赵清 思宇MedTech医疗科技媒体矩阵 创始人 分享内容： 大致围绕 ...

Core Viewpoint - Zhejiang Haisheng Medical Devices Co., Ltd. is entering the critical IPO review stage with the Beijing Stock Exchange, focusing on the development, production, and sales of anesthesia and monitoring medical devices [1][3] Group 1: Company Overview - The company has established a product matrix covering three main categories: anesthesia, monitoring, and surgical care, with eight major series including airway and respiratory management, life information monitoring, and spinal and nerve block [1] - Its products are widely used in over a thousand tertiary hospitals and thousands of medical institutions across China, including more than 600 top-tier hospitals such as Peking Union Medical College Hospital and Ruijin Hospital affiliated with Shanghai Jiao Tong University [1] Group 2: Financial and Operational Insights - In response to regulatory inquiries regarding the reasonableness of sales expense ratios, the company clarified that sales expenses are primarily allocated to academic promotion, dealer training, and market channel maintenance, aligning with industry peers like Weili Medical and Sanxin Medical [3] - The company plans to issue up to 11,294,118 shares to unspecified qualified investors, or up to 12,988,235 shares if the overallotment option is fully exercised, ensuring that public shareholders will hold at least 25% of the total share capital post-issuance [3] Group 3: Future Prospects - The raised funds will be used for upgrading and expanding production of emergency medical devices, establishing a research and testing center, and building a marketing service base [3] - With its core products already covering numerous key medical institutions and aligning with industry development trends, the company is expected to enhance its production capacity and technological transformation capabilities, thereby solidifying its competitive advantage in the anesthesia and monitoring medical device sector [3]

Core Viewpoint - Shenzhen Maikotian Biomedical Technology Co., Ltd. has submitted its IPO application to the Hong Kong Stock Exchange, aiming to expand its product lines and sales networks in the medical device sector, despite facing three consecutive years of net losses before 2024 [1][4]. Company Overview - Maikotian was established on April 26, 2011, previously known as Shenzhen Yusheng Medical Technology Co., Ltd. The company is headquartered in Nanshan District, Shenzhen [3]. - The company is led by Liu Jie, who has over 20 years of experience in the healthcare industry, including significant roles at Johnson & Johnson and Mindray Medical [3][4]. - The company has received multiple rounds of financing from various institutional investors, with a valuation of approximately 8.245 billion yuan in 2023 [4]. Product Portfolio - Maikotian's product offerings include life support, minimally invasive intervention, and in vitro diagnostics, with a total of over 350 commercialized products [6][7][10]. - The company has established a comprehensive distribution network, covering over 6,000 hospitals in China, including about 90% of tier-3 hospitals [6][19]. Financial Performance - The company's revenue has shown growth, with figures of 917 million yuan in 2022, 1.313 billion yuan in 2023, and 1.399 billion yuan in 2024, while the gross profit margins have improved from 43.7% in 2022 to 52.9% in the first half of 2025 [15][17]. - Despite revenue growth, the company reported net losses of 2.26 billion yuan in 2022, 645 million yuan in 2023, and 966 million yuan in 2024, primarily due to significant investments in R&D and marketing [15][22]. Market Position - The global market for life support medical devices is projected to reach 75.1 billion USD in 2024, with the Chinese market expected to reach 55.7 billion yuan [6]. - Maikotian ranks first in the infusion workstation market in China from 2018 to 2024 and holds a strong position in the minimally invasive intervention market [11][12][14]. R&D and Sales Strategy - The company has a dedicated R&D team of over 500 members, accounting for 25.1% of its total workforce, with R&D expenses amounting to approximately 934 million yuan over the reporting period [21][22]. - Sales expenses have consistently exceeded R&D expenses, indicating a strong focus on market penetration and distribution [22][23]. Distribution Network - Maikotian relies heavily on distributors for sales, with over 80% of its products sold through this channel. The company has a network of 1,959 domestic and 607 overseas distributors [19].

Core Viewpoint - The article discusses the termination of the IPO review for Beijing Tianxing Medical Co., Ltd. by the Shanghai Stock Exchange, primarily due to the withdrawal of the sponsor, China International Capital Corporation (CICC) [1] Group 1: Company Overview - Beijing Tianxing Medical Co., Ltd. is a leading domestic company in the field of sports medicine medical devices, with a net profit exceeding 60 million yuan [4] - As of September 30, 2024, the company has obtained 20 Class III medical device registration certificates and 17 Class II medical device registration certificates, along with CE certifications for 15 products [4] Group 2: Financial Performance - The company's revenue for the reporting periods was 73.01 million yuan, 147.97 million yuan, 241.19 million yuan, and 222.93 million yuan [5] - The net profit attributable to the parent company for the periods ending September 30, 2024, December 31, 2023, December 31, 2022, and December 31, 2021, was 64.08 million yuan, 63.58 million yuan, 40.34 million yuan, and -110.25 million yuan respectively [6] - The gross profit margin for the company during the reporting periods was 68.68%, 71.45%, 75.05%, and 69.71% [7] Group 3: Market Position - The company occupies approximately 4% of the sports medicine medical device market in China, ranking first among domestic enterprises [6] Group 4: Customer Base - The top five customers contributed significantly to the company's revenue, with the largest customer accounting for 18.39% of the revenue in the first nine months of 2024 [8] Group 5: Use of IPO Proceeds - The total amount to be raised from the IPO is 880 million yuan, which will be used for projects related to the company's main business, including a smart factory project and product development [8] Group 6: Shareholder Changes - The company had 12 new shareholders added in the year prior to the IPO application, indicating a shift in ownership structure [13]

文/西风 近日，深交所公布对赛克赛斯生物科技股份有限公司主板IPO终止审核的决定，直接原因是公司及保荐机构海通证券撤回申报。公司IPO于 2023年2月23日获得受 理，2023年5月23日公布首轮问询的回复，2023年12月30日公布首轮问询回复的更新版。2024年6月29日公布最新版本的招股书（申报稿）。公司本次IPO拟募资 4.55亿元。 公司注册地山东济南，前身山东赛克赛斯药业科技有限公司成立于2003年6月，2018年11月整体变更为股份公司，目前注册资本3.5008亿元。公司控股股东为山东 赛星控股集团有限公司，实际控制人为1977年出生的邹方明先生，拥有美国境外永久居留权。邹方明直接和间接合计控制公司 90.94%的股权，现任公司董事长。 一、2个产品技术水平国际先进，1个产品市占率第一 公司为一家专业从事植介入生物材料类医疗器械的研发、生产和销售的高新技术企业，在止血及手术防粘连类、组织封合及保护类、介入栓塞类、组织工程类等 生物材料领域拥有领先技术。目前拥有各类医疗器械产品 20 个，其中第三类医疗器械产品 8 个，3 个产品系国产独家产品；围绕 4 大生物材料领域共拥有主要在 研项目 11 ...